Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.

NCT00043303 is registered in ClinicalTrials.gov with InterMune as lead sponsor.

NCT NCT00043303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00043303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.
Lead sponsor
InterMune
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2001
Completion date
November 30, 2003
Enrollment
502 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver fibrosis